D&D Pharmatech Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
22
- Stock Symbol
-
347850
- Investments
-
2
- Share Price
-
$41.91
- (As of Friday Closing)
D&D Pharmatech General Information
Description
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.
Contact Information
Website
www.ddpharmatech.comCorporate Office
- 4th Floor, I&C Building
- 24, Pangyo-ro 255 beon-gil, Bundang-gu
- Seongnam-si, Gyeonggi-do 13486
- South Korea
Corporate Office
- 4th Floor, I&C Building
- 24, Pangyo-ro 255 beon-gil, Bundang-gu
- Seongnam-si, Gyeonggi-do 13486
- South Korea
D&D Pharmatech Stock Performance
As of 18-Apr-2025, D&D Pharmatech’s stock price is $41.91. Its current market cap is $442M with 10.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $41.91 | $35.99 | $17.99 - $44.02 | $442M | 10.5M | 249K | -$2.07 |
D&D Pharmatech Financials Summary
As of 31-Dec-2024, D&D Pharmatech has a trailing 12-month revenue of $8.38M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 333,617 | 333,617 | ||
| Revenue | 8,382 | 8,382 | 14,285 | 473 |
| EBITDA | (18,564) | (18,564) | 7,480 | (114,188) |
| Net Income | (20,978) | (20,978) | 3,009 | (105,305) |
| Total Assets | 66,193 | 66,193 | 61,461 | 74,147 |
| Total Debt | 6,641 | 6,641 | 6,312 | 21,564 |
D&D Pharmatech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
D&D Pharmatech Comparisons
Industry
Financing
Details
D&D Pharmatech Competitors (64)
One of D&D Pharmatech’s 64 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| BeiGene | Formerly PE-Backed | Beijing, China | ||||
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
| AbbVie | Corporation | North Chicago, IL |
D&D Pharmatech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
D&D Pharmatech Patents
D&D Pharmatech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023276018-A1 | Peptide compositions and methods of use threof | Pending | 27-May-2022 | ||
| GB-202418238-D0 | Peptide compositions and methods of use thereof | Pending | 27-May-2022 | ||
| EP-4531925-A1 | Compositions and methods for treatment of neurological disorders | Pending | 27-May-2022 | ||
| EP-4532530-A1 | Peptide compositions and methods of use threof | Pending | 27-May-2022 | ||
| GB-2634433-A | Peptide compositions and methods of use thereof | Pending | 27-May-2022 | C07K14/605 |
D&D Pharmatech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
D&D Pharmatech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
D&D Pharmatech Investments & Acquisitions (2)
D&D Pharmatech’s most recent deal was a Merger/Acquisition with Neuraly. The deal was made on 01-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neuraly | 01-Jan-2019 | Merger/Acquisition | Drug Discovery | ||
| Neuraly | 18-Jul-2018 | Early Stage VC | Drug Discovery |
D&D Pharmatech Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Neuraly | Gaithersburg, MD | 2016 |
D&D Pharmatech FAQs
-
When was D&D Pharmatech founded?
D&D Pharmatech was founded in 2014.
-
Where is D&D Pharmatech headquartered?
D&D Pharmatech is headquartered in Seongnam-si, South Korea.
-
What is the size of D&D Pharmatech?
D&D Pharmatech has 22 total employees.
-
What industry is D&D Pharmatech in?
D&D Pharmatech’s primary industry is Pharmaceuticals.
-
Is D&D Pharmatech a private or public company?
D&D Pharmatech is a Public company.
-
What is D&D Pharmatech’s stock symbol?
The ticker symbol for D&D Pharmatech is 347850.
-
What is the current stock price of D&D Pharmatech?
As of 18-Apr-2025 the stock price of D&D Pharmatech is $41.91.
-
What is the current market cap of D&D Pharmatech?
The current market capitalization of D&D Pharmatech is $442M.
-
What is D&D Pharmatech’s current revenue?
The trailing twelve month revenue for D&D Pharmatech is $8.38M.
-
Who are D&D Pharmatech’s competitors?
Astellas Pharma, Cytovance Biologics, BeiGene, Coherus Biosciences, and AbbVie are some of the 64 competitors of D&D Pharmatech.
-
What is D&D Pharmatech’s annual earnings per share (EPS)?
D&D Pharmatech’s EPS for 12 months was -$2.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
